Overview

FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine

Status:
Active, not recruiting

Trial end date:
2020-07-01

Target enrollment:

Participant gender:

Summary

The main objective of this trial is to evaluate every 2 months alternating nab-paclitaxel/gemcitabine and FOLFIRI.3 versus nab-paclitaxel + gemcitabine, regarding the progression of disease at 6 months.

Phase:

Phase 2

Details

Lead Sponsor:

Federation Francophone de Cancerologie Digestive

Collaborators:

GERCOR - Multidisciplinary Oncology Cooperative Group
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
UNICANCER

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel